Your browser doesn't support javascript.
Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro.
Pasquereau, Sébastien; Nehme, Zeina; Haidar Ahmad, Sandy; Daouad, Fadoua; Van Assche, Jeanne; Wallet, Clémentine; Schwartz, Christian; Rohr, Olivier; Morot-Bizot, Stéphanie; Herbein, Georges.
  • Pasquereau S; Pathogens & Inflammation/EPILAB Laboratory, EA 4266, Université de Franche-Comté, Université Bourgogne Franche-Comté (UBFC), 25030 Besançon, France.
  • Nehme Z; Pathogens & Inflammation/EPILAB Laboratory, EA 4266, Université de Franche-Comté, Université Bourgogne Franche-Comté (UBFC), 25030 Besançon, France.
  • Haidar Ahmad S; Lebanese University, P.O. Box 6573/14 Badaro Museum, Beirut, Lebanon.
  • Daouad F; Pathogens & Inflammation/EPILAB Laboratory, EA 4266, Université de Franche-Comté, Université Bourgogne Franche-Comté (UBFC), 25030 Besançon, France.
  • Van Assche J; Lebanese University, P.O. Box 6573/14 Badaro Museum, Beirut, Lebanon.
  • Wallet C; FMTS, EA7292, Université de Strasbourg, IUT Louis Pasteur, 67300 Schiltigheim, France.
  • Schwartz C; FMTS, EA7292, Université de Strasbourg, IUT Louis Pasteur, 67300 Schiltigheim, France.
  • Rohr O; FMTS, EA7292, Université de Strasbourg, IUT Louis Pasteur, 67300 Schiltigheim, France.
  • Morot-Bizot S; FMTS, EA7292, Université de Strasbourg, IUT Louis Pasteur, 67300 Schiltigheim, France.
  • Herbein G; FMTS, EA7292, Université de Strasbourg, IUT Louis Pasteur, 67300 Schiltigheim, France.
Viruses ; 13(2)2021 02 23.
Article in English | MEDLINE | ID: covidwho-1100154
ABSTRACT
A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China at the end of 2019 causing a large global outbreak. As treatments are of the utmost importance, drug repurposing embodies a rich and rapid drug discovery landscape, where candidate drug compounds could be identified and optimized. To this end, we tested seven compounds for their ability to reduce replication of human coronavirus (HCoV)-229E, another member of the coronavirus family. Among these seven drugs tested, four of them, namely rapamycin, disulfiram, loperamide and valproic acid, were highly cytotoxic and did not warrant further testing. In contrast, we observed a reduction of the viral titer by 80% with resveratrol (50% effective concentration (EC50) = 4.6 µM) and lopinavir/ritonavir (EC50 = 8.8 µM) and by 60% with chloroquine (EC50 = 5 µM) with very limited cytotoxicity. Among these three drugs, resveratrol was less cytotoxic (cytotoxic concentration 50 (CC50) = 210 µM) than lopinavir/ritonavir (CC50 = 102 µM) and chloroquine (CC50 = 67 µM). Thus, among the seven drugs tested against HCoV-229E, resveratrol demonstrated the optimal antiviral response with low cytotoxicity with a selectivity index (SI) of 45.65. Similarly, among the three drugs with an anti-HCoV-229E activity, namely lopinavir/ritonavir, chloroquine and resveratrol, only the latter showed a reduction of the viral titer on SARS-CoV-2 with reduced cytotoxicity. This opens the door to further evaluation to fight Covid-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Virus Replication / Ritonavir / Coronavirus 229E, Human / Resveratrol / SARS-CoV-2 Type of study: Experimental Studies Topics: Variants Limits: Humans / Male Language: English Year: 2021 Document Type: Article Affiliation country: V13020354

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Virus Replication / Ritonavir / Coronavirus 229E, Human / Resveratrol / SARS-CoV-2 Type of study: Experimental Studies Topics: Variants Limits: Humans / Male Language: English Year: 2021 Document Type: Article Affiliation country: V13020354